• Home
  • Recent News and Upcoming Events

Recent News and Upcoming Events

Recent News

Choose a Category:

  • Aspira Women’s Health Releases Analytical and Initial Clinical Validation Performance for OVASight at ASCO 2021

    For a PDF version of this press release, click here. Data demonstrates the performance of OVASight in a low prevalence population-89% Specificity, 91% Sensitivity and a Negative Predictive Value of 99.6%for the management of suspected Benign Pelvic Masses AUSTIN, Texas; June 3, 2021 – Aspira Women’s Health Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company focused on…

  • May is Mental Health Awareness Month

    COVID-19 has had a profound impact on the mental health of so many people of all ages.  Women diagnosed with ovarian cancer also face an increased risk of mental illness.  In fact, according to a recent study, “Women diagnosed with ovarian cancer were more than three times more likely than the general public to be…

  • Aspira Women’s Health Inc. to Participate in the William Blair Growth Stock Conference

    For a PDF of this press release, click here. AUSTIN, Texas — May 19, 2021 — Aspira Women’s Health, Inc. (Nasdaq: AWH), a bioanalytical-based women’s health company, today announced that management will participate in and present at the William Blair Growth Stock Conference on June 1-3, 2021. Details for the event are below: William Blair…

  • Aspira Women’s Health Reports First Quarter 2021 Financial Results

    Conference call scheduled for today, May13 at 4:30 p.m. ET For a PDF of this press release, click here. AUSTIN, Texas — May 13, 2021 — Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on gynecologic disease, today reported its financial results for the first quarter ended, March 31, 2021. “We…

  • Aspira Women’s Health to Reveal 3rd Generation Ovarian Cancer Risk Assessment Technology at ASCO 2021

    For a PDF of this press release, click here. Analytical and Initial Clinical Validation performance for Aspira’s OVASightTM blood-based biomarker test for Ovarian Malignancy risk assessment in women with Adnexal Masses. Data demonstrates the ability to identify Ovarian Cancer Risk in a low prevalence population. AUSTIN, Texas; May 13, 2021 – Aspira Women’s Health, Inc. (Nasdaq:…

Investor Relations